Comments
Cipla will invest around Rand 1.3 billion (over Rs 590 crore) to launch a manufacturing facility in South Africa for the production of biosimilars.
The company’s “proposed biotech subsidiary in South Africa will invest just over R 1.3 billion into the country’s first state-of-the-art biotech manufacturing facility, for the production of biosimilars,” Cipla said in a statement.
According to the statement, a memorandum of understanding between Cipla BioTec Pvt Ltd and Dube Tradeport Corporation will be signed.
The facility will manufacture biosimilar drugs made from living organisms that would be used in the treatment of cancer and other diseases. Construction is scheduled to start in early 2017, with full operations expected to commence in the third quarter of 2018, Cipla said.
Commenting on the development, Cipla MD & Global CEO Subhanu Saxena said a manufacturing base in South Africa will give opportunities for supply chain partners and related companies to get involved.
Cipla’s investment in this facility will enable the creation of the first bio-cluster on the African continent, he added.
Shares of the company ended higher by 1.27 per cent at Rs 519.75 on the BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.